What does "microdosing" a weight-loss injection mean?
It is an online label, not a medical one. In the posts and listings that use it, it usually means taking a small fraction of the usual dose of tirzepatide (sold as Mounjaro) or semaglutide (sold as Ozempic and Wegovy), sometimes by dividing a pen or by measuring from a vial. The promises are that it costs less, that it causes fewer side effects, or that it "resets" appetite gently.
No licensed product carries that name, and none of the trials cited here tested it. Cost and discomfort are real pressures, which is why the idea spreads. The question is whether the idea has any evidence or safety behind it.
What are the licensed dose steps?
Both medicines already start low. In the European product information, tirzepatide starts at 2.5 mg once weekly. After four weeks the dose goes to 5 mg, and if more is needed it rises in 2.5 mg steps, each after at least four weeks on the current dose. The recommended adult maintenance doses are 5 mg, 10 mg and 15 mg, with 15 mg the maximum.
Semaglutide as Wegovy follows a similar ladder. It starts at 0.25 mg once weekly, then 0.5 mg, 1 mg and 1.7 mg, each for four weeks, reaching 2.4 mg from week 17. The product information says the dose is stepped up to reduce the chance of stomach symptoms. These are the steps printed on the label, not an instruction to anyone. A prescriber decides the dose for each person, and the leaflet registered for the product you are given may differ in detail.
In other words, the gentle start people are seeking is already built in. The side effects most people meet cluster around those early steps, which is covered in the page on weight-loss injection side effects.
What did lower doses actually do in the trials?
In SURMOUNT-1, 2539 adults without diabetes were given tirzepatide 5 mg, 10 mg or 15 mg, or placebo, for 72 weeks, including a 20-week period of stepping up. Mean weight change at week 72 was -15.0% with 5 mg, -19.5% with 10 mg, -20.9% with 15 mg and -3.1% with placebo. The most common adverse events were gastrointestinal, mostly mild to moderate, and they occurred mainly during the dose-escalation period.
This is the trial most often quoted to support "a lower dose still works", and it needs reading carefully. The 5 mg group received a full 5 mg weekly dose after stepping up under trial conditions, with a regulated product and lifestyle support. It tells us about a licensed lower maintenance dose. It does not tell us about a fraction of a pen, a diluted vial or a product of unknown strength.
The semaglutide trial, STEP 1, enrolled 1961 adults and tested 2.4 mg against placebo for 68 weeks: a mean -14.9% against -2.4%. It tested one dose, so it cannot say what a lower dose would have done. How tirzepatide and semaglutide compare overall is set out in the comparison of GLP-1 medicines, and the mechanism of the first is in the tirzepatide explainer.
Why is splitting a pen or measuring from a vial unsafe?
Because accuracy depends on the product being used the way it was designed and tested. In July 2024 the US FDA reported adverse events, some needing hospital care, linked to dosing errors with compounded semaglutide sold in multi-dose vials. Patients measuring their own doses took 5 to 20 times the intended amount. In one example, a patient meant to draw 5 units and drew 50. Providers also made errors converting milligrams to units or millilitres, giving 5 to 10 times the intended dose in some cases.
The effects listed included severe nausea and vomiting, abdominal pain, fainting, headache, dehydration, acute pancreatitis and gallstones. The FDA named confusion between millilitres, milligrams and "units" as a cause, and noted many patients had no experience of self-injecting. Those reports concern compounded vials in the United States, but the lesson travels: a small-dose plan that depends on the person measuring a tiny volume is the plan most exposed to a measuring mistake, and in the FDA's examples the errors ran toward a larger dose.
What about vials and pens bought online?
A product that is not registered has not been checked by the regulator for what it contains, how strong it is or how it was made. A low price is part of why these listings attract buyers, and it is also part of why a listing can be a counterfeit, an unregistered import or something relabelled. The page on buying Ozempic or Mounjaro online in Malaysia explains why a prescription matters, and how to check if a product is KKM approved shows the steps to verify a product.
Stretching a supply by dividing it adds a second risk on top of the first. Not knowing the strength of what is in the vial and measuring a fraction of it by eye is a combination no trial has examined.
Is there ever a reason to stay on a lower dose?
Yes, and it belongs to the doctor prescribing it. The tirzepatide product information lists 5 mg as a recommended maintenance dose. The semaglutide leaflet tells a person who is very bothered by nausea or vomiting to talk to their doctor about delaying a dose step or going back to the previous dose until symptoms ease. Staying at a lower dose for tolerability is therefore within the labelling, as a clinical decision made with someone who knows the person's history, other medicines and goals.
If side effects are the worry, or the cost, the safe move is to say so to the prescriber and not to change the dose alone. A doctor can adjust the plan, review whether the medicine is right, and check that the product in hand is genuine.
